Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine and Celecoxib for Newly-Infected COVID-19 Patients
NCT05077969Phase 2Terminated
- Sponsor
- Leidos
- Start
- Dec 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famotidine, celecoxib oral solution in coronavirus disease 2019 (COVID-19), sponsored by Leidos. Started Dec 2021; status: terminated.
02
Drugs
famotidinecelecoxib oral solution
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05077969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05077969.